Water Street Appoints Vice President
Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced today that it has appointed Nicklaus Daley to vice president.
Mr. Daley augments Water Street’s team of senior investment professionals and former executives of health care corporations including Baxter International Inc., CVS Caremark Corporation, Johnson & Johnson and McKesson Corporation.
Mr. Daley will support Water Street with identifying and executing new investment opportunities in the firm’s targeted health care sectors. He also will assist with the strategic management of Water Street’s group of health care companies. Prior to Water Street, Mr. Daley worked as an associate with CIVC Partners. He also worked at Houlihan Lokey and the consulting practice of Bain & Company. Mr. Daley received his bachelor’s degree in economics from the Wharton School at the University of Pennsylvania. He earned his master’s degree in business administration from Northwestern University’s Kellogg School of Management.
“We are pleased to grow Water Street as we continue to expand our family of health care companies. It has been a busy year with our team investing in a services company and facilitating four strategic acquisitions to strengthen and extend our companies’ capabilities,” said Tim Dugan, managing partner, Water Street. “We continue to be focused on proactively engaging with health care leaders to discuss new ways that we can align our team’s health care expertise and resources to support them in achieving their objectives for value creation.”
Water Street has completed more than 70 strategic acquisitions and mergers to build 25 market-leading health care companies since raising its first fund 10 years ago. The firm recently announced that it signed an agreement to sell its specialty clinical trial solutions business, Bioclinica, Inc. Water Street is continuing to pursue proprietary investment opportunities in four segments of health care: medical and diagnostic products and devices, specialty distribution, health care services, and specialty pharmaceutical products and services. Target investments range in size from $50 million to $500 million in value.